GeneType and Humanise Health host “Know Your Risk” Event

PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the Know Your Risk event held yesterday at The Langham Pasadena has set a new standard for women’s health initiatives, highlighting the transformative potential of genetic testing and risk assessment. Organized by GeneType and Humanise Health, in partnership with Thermo Fisher Scientific and Creators Entertainment Group, this landmark event was not merely a gathering, but a movement aimed at empowering women with the knowledge to take control of their health.

A Movement, Not Just an Event

The Know Your Risk event was designed to foster an environment where women could engage with cutting-edge discussions on genomics and the importance of personalized health strategies. Through thought-provoking sessions led by renowned healthcare professionals, attendees explored how genetic testing and risk assessment can revolutionize preventive healthcare for women.

Inspirational Speakers and Insightful Panels
Co-hosted by the esteemed Dr. Kristi Funk and the dynamic Krystal Barter, the event featured a series of enlightening panels. Dr. Funk, Angelina Jolie’s Breast Surgeon, and Krystal Barter, along with an impressive lineup of speakers including Dr. Carolynn Young, Andrea Hans, Allyn Rose Oertel, and Matthew Zachary, provided invaluable insights into the critical role of genomics in women’s health.

Key Sessions Included:

Unpacking the Gender Health Gap: The Vital Role of Genetic Testing and Risk Assessment in Cancer Prevention for Women’s Health – Dr. Kristi Funk, Dr. Carolynn Young, and Krystal Barter delved into how genetic testing can identify risks early, bridging the gap in gender-specific healthcare.

Patient Voices at the Center: Lived Experiences in Women’s Health Advocacy and Policy – Andrea Hans, Matthew Zachary, and Allyn Rose Oertel shared personal stories and discussed the impact of patient advocacy on health policies and practices.

Launch of the Revolutionary GeneType Test
A highlight of the event was the launch of the groundbreaking geneType hereditary breast and ovarian cancer test. This innovative test is designed to identify 100 percent of women at risk, including those with the most common gene mutations, regardless of family history. This advancement represents a significant leap forward in preventive healthcare, offering women the tools they need to make informed decisions about their health.